Duchenne Muscular Dystrophy

WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
Fri, 12/23/16 - 10:01 am
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Wed, 12/21/16 - 10:52 am
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Thu, 12/15/16 - 10:05 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Endpoints
Wed, 12/14/16 - 09:18 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sun, 11/13/16 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
Sat, 11/5/16 - 01:25 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA official warns other drug makers not to copy Sarepta
Stat/Pharmalot
Thu, 10/20/16 - 08:16 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
PTC shares plunge anew after FDA slaps down Duchenne drug for a second time
Endpoints
Mon, 10/17/16 - 11:46 pm
PTC Therapeutics
FDA
Duchenne Muscular Dystrophy
Translarna
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Mon, 10/17/16 - 11:41 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Major US insurer snubs Sarepta's Duchenne drug
BioPharma Dive
Mon, 10/10/16 - 09:18 am
Anthem
insurerrs
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Yahoo/Benzinga
Tue, 10/4/16 - 03:58 pm
Sarepta Therapeutics
Europe
Duchenne Muscular Dystrophy
Summit Therapeutics
ezutromid
The Woman Behind Sarepta Therapeutics' Success
Motley Fool
Mon, 09/26/16 - 09:38 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Kyndrisa
FDA
Janet Woodcock
Sarepta quickly lays out manufacturing, launch plans after delayed approval of Duchenne MD drug
Fierce Pharma
Sat, 09/24/16 - 01:32 pm
Sarepta Therapeutics
Kyndrisa
Duchenne Muscular Dystrophy
FDA approval in hand, Sarepta plans for future studies
BioPharma Dive
Fri, 09/23/16 - 09:44 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Kyndrisa
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Fri, 09/23/16 - 09:35 am
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
FDA commissioner calls for Sarepta drug study to be retracted
Stat/Pharmalot
Thu, 09/22/16 - 12:18 pm
FDA
Sarepta Therapeutics
Robert Califf
Duchenne Muscular Dystrophy
eteplirsen
Sarepta's New Drug May Make It a Takeover
Investopedia
Wed, 09/21/16 - 10:50 pm
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
M&A
Sarepta, Patients Win - But What Of Regulatory Oversight?
Seeking Alpha
Tue, 09/20/16 - 11:10 am
Sarepta Therapeutics
regulatory
Duchenne Muscular Dystrophy
FDA
eteplirsen
Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
Stat/Pharmalot
Tue, 09/20/16 - 09:49 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
drug pricing
eteplirsen

Pages